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Furthermore, in a computational simulation of circulating tumor DNA, we were able to detect limited amounts
of tumor DNA diluted with normal DNA: 1% tumor DNA in 99% normal DNA yields AUCs of up to 0.79. Our
ﬁndings suggest that hypermethylation of the ZNF154 CpG island is a relevant biomarker for identifying solid
tumor DNA and may have utility as a generalizable biomarker for circulating tumor DNA. (J Mol Diagn 2016,
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Disclosures: None declared.One in four deaths in the United States is due to cancer,
despite an emphasis on prevention, early detection, and
treatment that has lowered cancer death rates by 20% in the
past two decades.1,2 Further improvements in survival rates
are likely to come from improving the limits of detection
sensitivity at earlier stages of cancer. Currently, a diagnosis
results from a cadre of screening and diagnostic tools that
may include physical examination, radiographic imaging,
sputum cytologic testing, blood tests, endoscopy, and/or
biopsies. However, new approaches that rely heavily on
genomic information may change future testing strategies.merican Society for Investigative Pathology an
Y-NC-ND license (http://creativecommons.orgThe future looks bright because minimally invasive sam-
pling techniques coupled with genomic features that distin-
guish tumor cells from normal cells have the potential to detect
cancer at earlier stages. For example, circulating tumor cells or
cell-free plasma DNA can be detected in venous peripheral
blood and tested for the presence of common mutations.3
Cell-free tumor DNA can also be detected in buccald the Association for Molecular Pathology.
/licenses/by-nc-nd/4.0).
Margolin et alepithelium, saliva, urine, stools, and bronchial aspirates.4 Such
DNA has been used to detect mutations in patients with both
localized and metastatic cancers.5 Moreover, somatic muta-
tions in ovarian and endometrial cancers can potentially be
detected using Papanicolaou specimens.6
In addition to genetic mutations, epigenetic markers are
emerging as tools with discriminatory power for disease detec-
tion. For example, DNA methylation is a robust epigenetic
marker forwhich a number of commercially available tests have
been developed. These tests detect tissue-speciﬁc DNA
methylation using clinical specimens and are used in colorectal
cancer (SEPT9, blood; VIM, stool), lung cancer (SHOX2,
bronchial ﬂuid), and brain cancer (MGMT, tumor).7 One
advantage of this approach is marker stability under common
storage conditions.4 However, despite DNA methylation’s
potential as a diagnostic marker, a general lack of consensus on
the methods remains. This is the principal reason for its slow
implementation in clinical diagnostics.4,7
Previously, our laboratory reported a pan-cancer hyper-
methylation signal around a CpG island near human ZNF154.8
This signal was initially detected by us in ovarian and endo-
metrial cancers and replicated by us in multiple, independent
cohorts from The Cancer Genome Atlas (TCGA), incorpo-
rating a total of 15 distinct tumor collections from 13 different
organs with almost 6000 samples.8 These previous analyses
relied on data generated from Illumina Inﬁnium methylation
arrays (Illumina Inc, San Diego, CA) to detect the methylation
levels at select CpG sites. In this study, we measure the
ZNF154 methylation signal across ﬁve tumor types using
bisulﬁte amplicon sequencing. With this method, individual
sequence reads are used to quantitate methylation levels of all
CpGs within the amplicon while providing quantitative data
for each DNA molecule in the pooled sample. Furthermore,
the approach provides an intrinsic measure of quality control
by tracking bisulﬁte conversion efﬁciency at cytosines in the
non-CpG context wherein extensive amounts of unconverted
cytosines signal an incomplete conversion reaction. This
procedure is both time efﬁcient and cost-effective because
multiple samples can be sequenced in parallel using a 96-well
plate and, as we report, generate reproducible measurements
when assayed in independent experiments. The amplicon
sequencing provides greater resolution of a target region than a
methylation array by covering all ampliﬁed CpGs, revealing
patterns of DNA methylation useful for distinguishing tumor
from normal samples.
We report that the magnitude and reproducibility of the
ZNF154 hypermethylation signal across ﬁve solid tumor
types reinforces the potential of this site as a biomarker for
circulating tumor DNA (ctDNA). Next, we assess the
potential application of various computational data clas-
siﬁcation methods toward cancer screening. By investi-
gating a variety of technical approaches to characterize
methylated bases within the sequenced samples, we iden-
tify features useful for distinguishing tumor samples from
normal samples. Finally, we use a computational simula-
tion to demonstrate the utility of these features in284classifying samples as tumor or normal tissue at various
abundance levels; here, tumor DNA methylation patterns
are compiled into a background of normal DNA methyl-
ation patterns, at limiting dilution levels, mimicking the
fractions at which ctDNA is recovered from blood.Materials and Methods
Sample Preparation
GM12878 and K562 Cell Lines
GM12878 is a lymphoblastoid cell line with a relatively
normal karyotype and low DNA methylation levels. It was
obtained from the Coriell Institute for Medical Research
(catalog no. GM12878; Camden, NJ). K562 is an immor-
talized chronic myelogenous leukemia cell line. It has high
methylation levels compared with GM128788 and was
obtained from the ATCC (catalog no. CCL-243; Manassas,
VA). Genomic DNA from GM12878 cells and K562 cells
was harvested in triplicate using the QiaAmpDNAMini Kit
(catalog no. 51304), and DNA from each replicate was
serially diluted to 100, 50, and 20 ng of total starting ma-
terial, in duplicate (thus yielding 18 replicate samples per
cell line). During the bisulﬁte conversion step, nine samples
failed, wherein six were generated from the 100-ng
dilutions.
Gynecologic Samples
The Cooperative Human Tissue Network, funded by the
National Cancer Institute, provided eight normal endometrial
tissue samples. DNA was extracted using the QiaAmp DNA
Mini Kit (catalog no. 51304; Qiagen, Hilden, Germany), DNA
quality was assessed using the 260:280 ratio measured with a
NanoDrop spectrophotometer, and DNA was quantiﬁed with
a Qubit ﬂuorometer (Invitrogen, Carlsbad, CA). Samples
consisted of atrophic endometrium obtained from routine
hysterectomy or pelvic resection for nonendometrial cancers in
postmenopausal individuals. In addition, 42 endometrial tumor
samples were obtained from the Cooperative Human Tissue
Network. They included 20 endometrioid carcinomas (EECs),
11 serous tumors, and 11 clear cell tumors. Tissues were snap
frozen after surgery and stored at 80C. Genomic DNA was
isolated using the Puregene Blood Kit (Qiagen) following the
manufacturer’s instructions. DNA quality and concentration
were assessed using a SmartSpec Plus spectrophotometer
(BioRad, Hercules, CA).
Lung, Stomach, Colon, and Breast Tumor Panels
We purchased 96-well plates that contained genomic DNA
from tumor and normal samples for each tumor type from
Amsbio (Cambridge, MA). Normal DNA was obtained from
pathologically normal donors; samples were not isolated
from normal adjacent tissues from donors with tumors. Amsbio
extracted genomic DNA from a variety of frozen tissues using a
modiﬁed guanidine thiocyanate technique and dissolved it in
1 TE buffer (10 mmol/L Tris, pH 8.0, 1 mmol/L EDTA).jmd.amjpathol.org - The Journal of Molecular Diagnostics
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samples in technical duplicates. Each well contained 5 mL of
genomic DNA at approximately 4 ng/mL, yielding 20 3 ng of
genomic DNA per sample (mean  SD).Methylation Analysis
Each dilution of genomic DNA was bisulﬁte converted with
the EZ DNA Methylation-Direct Kit (catalog no. D5020 for
a single sample or D5023 for the plate; Zymo Research,
Irvine, GA), PCR ampliﬁed, and sequenced.
Human Methylation Array
Gynecologic samples were analyzed with the Human-
Methylation27 Illumina BeadChip. The hybridization
reaction was performed according to the manufacturer
protocol, and samples were scanned using the Illumina
iScan System.
Amplicon Generation
To generate a 302-bp PCR product from ZNF154, we used
forward (50-GGTTTTTATTTTAGGTTTGA-30) and reverse
(50-AAATCTATAAAAACTACATTACCTAAAATACTC-
TA-30) primers. The primers contained different adapters at
their 50 ends: forward adapter: 50-ACACTCTTTCCCTAC-
ACGACGCTCTTCCGATCT-30, reverse adapter: 50-GTG-
ACTGGAGTTCAGACGTGTGCTCTTCCGATCT-30. The
primer design assumed all non-CpG Cs are converted with
sodium bisulﬁte to Ts. The primers annealed to regions in the
genomic DNA sequence devoid of any cytosines in a CpG
context. PCR reactions contained 0.25 mL of 5-U/mL TaKaRa
EpiTaq HS DNA Polymerase (for bisulﬁte-treated DNA)
with 10 EpiTaq PCR Buffer, 5 mL of 25 mmol/L MgCl2,
6 mL of 2.5 mmol/L dNTP mix (catalog no. R110A;
TaKaRa Bio Inc., Kusatsu, Japan), and 1 mL each primer at
12.5 mmol/L in 50-mL total volume. Cycling conditions
were 95C for 10 minutes, 45 cycles of 95C for 30 sec-
onds, 48C for 30 seconds, and 72C for 60 seconds, and
72C for a 7-minute ﬁnal extension. PCR products were
veriﬁed by electrophoresis on a 2% agarose gel.
After PCR, one or two rounds of product cleanup were
performed by adding 37.5 mL of Agencourt Ampure XP
PCR Puriﬁcation Beads [catalog no. A63881; Beckman
Coulter Genomics (formerly Agencourt), Danvers, MA]
to the 50-mL PCR mixture. PCR products were veriﬁed by
electrophoresis on a 2% agarose gel. Following cleanup,
barcodes (Illumina Amplicon Indexing Oligos) were
added in a second round of PCR, using 25 mL of 2
Phusion Master Mix (catalog no. M0531L; New England
Biolabs Inc., Ipswich, MA) and 1 mL each bar-coded
primer at 25 mmol/L in 50-mL total volume. Cycling
conditions were 98C for 30 seconds, 8 cycles of 98C for
10 seconds, 65C for 30 seconds, and 72C for 30 sec-
onds, and 72C for a 5-minute ﬁnal extension. A ﬁnal
round of XP PCR puriﬁcation bead cleanup was applied,
as before, to remove excess bar-coding oligonucleotides.The Journal of Molecular Diagnostics - jmd.amjpathol.orgAmplicon Sequencing
PCR products were sequenced at the NIH Intramural
Sequencing Center using the Illumina MiSeq platform with
reagent kit version 3 (Illumina Inc.) to generate paired-end,
300-bp reads (200 bp for the lung plate). Brieﬂy, agarose gel
analysis was performed for each well in the 96-well
amplicon plate. On the basis of the intensity of the prod-
uct bands, the relative concentration of each sample was
estimated. Using these values, a pool was created that
adjusted for relative differences. The concentration of this
pool was determined using the Illumina/Universal Library
Quantiﬁcation Kit (Kapa Biosystems Inc., Wilmington,
MA). An aliquot of the pool was run on a MiSeq (Illumina
Inc.) using a MiSeq Reagent Nano kit version 3. This
quality control run consisted of 25 cycles followed by a
6-cycle index read, which provided an accurate proﬁle of the
representation of the samples in the pool. If necessary, an
additional volume of poorly represented amplicons was
added to the pool. The ﬁnal pool was then sequenced on the
MiSeq. Both MiSeq runs were spiked with a PhiX control
library to improve base diversity. The PhiX library typically
accounted for 30% to 50% of reads. Postrun processing of
data were performed using RTA version 1.18.42 and
CASAVA software version 1.8.2 (Illumina Inc.).
Presentation of Changes in Methylation
We report methylation levels in percentages or fractions
(percentage per 100). Importantly, to avoid possible confusion,
when we note a methylation difference of X%, we refer to an
absolute difference of X units (0 to 100), not a relative X%
change from the current methylation level. For example, if the
reference methylation level is 30%, then a 10% difference
from the reference level indicates 20% or 40% methylation,
not 27% or 33%.
Alignment of Sequencing Data
We have observed that base quality deteriorates substan-
tially in the second half of the paired-end sequence reads,
especially the second reads. Therefore, because the reads
were expected to overlap, we adjoined the ﬁrst 200 bp from
the ﬁrst read to the ﬁrst 102 bp from the second read (after
reverse complementation) to produce single fragments of
the expected 302-bp length.
We aligned the resulting full-length fragments to the human
genome version GRCh37/hg19 using Bismark version 0.7.12.9
This procedure ﬁltered out nonaligning reads and returned the
number of aligned reads and methylation levels at each C,
including each of the 20 CpGs in the amplicon and cytosines
in non-CpG contexts, and mean methylation across each
sample in CpG, CHG, and CHH contexts (where H represents
A, C, or T). Non-CpG methylation was used as an internal
upper-bound estimate of the inefﬁciency of bisulﬁte conver-
sion because little appreciable cytosine methylation occurs
outside CpG dinucleotides. Moreover, the alignment ﬁles
contained the patterns of methylated bases within individual
sequence reads.285
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aligned to the genome out of total sequenced reads) varied
from 0% to 89% (median, 18%) across sample replicates.
Most, if not all, of the unaligned reads show clear primer
dimer signatures, such as repeated forward and/or reverse
primer and adaptor sequences, and typical poly-A artifactual
base calls extending beyond the actual fragment size. These
fragments were the most likely cause of the additional lower
bands observed on our agarose gels; however, genomic
alignment effectively ﬁlters them from the analysis.
The fraction of cytosine nonconversion in non-CpG
contexts calculated by the Bismark application is, in
fact, an underestimate because it takes into account the
cytosines in the primer regions, which are expected to
be always converted due to primer design (the primers
hybridize only to Cs that are converted to uracil). To
directly estimate nonconversion percentages in the
aligned reads, we examined the Cs in a CHG and CHH
context. The 302-bp ZNF154 amplicon contains 14 Cs
in a CHG context (two within each of the primer re-
gions and 10 between) and 59 Cs in a CHH context
(six and four within the forward and reverse primers,
respectively, and 49 between). Therefore, Bismark es-
timates were corrected by factors of 14/10 Z 1.40 and
59/49 Z 1.20 for CHG and CHH contexts, respectively.
Indeed, when we directly analyzed nonconversion per-
centages in the aligned reads, excluding cytosines
within primer regions, the slopes in linear regressions
of our direct estimates versus Bismark estimates closely
agreed with these factors: 1.35 and 1.22 for CHG and
CHH contexts, respectively.
We use the nonconversion percentage in non-CpG
context as an upper limit of the inefﬁciency of sodium
bisulﬁte treatment. Assuming a similar effect at all cyto-
sines, we can correct the reported CpG methylation levels.
In this way, we calculate a true percentage of methylation
CpG as mt Z 100 (mo  e)/(100  e), where mo is the
observed percentage of mCpG, and e is the nonconversion
percentage of unmethylated cytosines. Hence, the differ-
ence between the observed and true levels is mo  mt Z
(100  mo) e/(100  e).
Taking the maximum of the four estimates of non-CpG
methylation/nonconversion for each sample as e (ie, two direct
estimates for CHG and CHH contexts, as described above, and
two estimates from Bismark), the median correction in per-
centage of mCpG, or the median of mo  mt, was 0.4, and the
maximum was 2.8 (on a scale of 0 to 100). Given such a small
effect, we kept the uncorrected values.
Sample Reproducibility
Comparison of sample duplicates in the four 96-well
tumor plates revealed that duplicates with >1000 aligned
reads closely agreed, in accord with recent reports.10
However, two outlier samples on the colon plate had
duplicate methylation signals of 60% and 20% (with
>1000 aligned reads in each duplicate), indicating that286duplicates from the two samples had been inadvertently
swapped. These samples were removed from the analysis.
To maximize the number of samples retained for further
analysis, we summed reads from both duplicates for each
sample. A sample was retained if there were >1000
aligned reads in total unless the following two conditions
occurred: each duplicate had >250 aligned reads, and
mean CpG methylation differed by >0.2 (20%) between
duplicates. The last condition excluded the two suspicious
colon samples (but nothing else).
Analysis of Clinical Data
Most postalignment analysis was performed using the R
language for statistical computing version 3.1.1 (http://www.
r-project.org).11We used analysis of variance (R functions lm
and anova) to regress mean sample methylation on age, sex,
and tumor diagnosis (subtype and differentiation level or
grade). We used both a full and shortened version of diag-
nostic data; the shortened version excluded tumor differenti-
ation levels (not available for stomach) and produced fewer
categories, with larger sample sizes. We used single-term
deletions in the model (R function drop1) to estimate the
signiﬁcance of these predictors; there were no interaction
terms in the model.
Extraction of Sequencing Read Methylation Patterns
Most aligned reads (approximately 99.5%) had the expected
starting coordinate (chr19:58220404); most of the rest
aligned to neighboring bases, with several single-occurrence
exceptions. Only reads with 20 CpGs (based on Bismark
context calls) that were aligned to the expected starting
coordinate were retained, yielding 93% to 98% (median,
96%) of the aligned reads reported by Bismark application.
This ﬁnding is consistent with a Phred base quality score of
approximately 30 (ie, a base call error rate of 0.001). The 20
CpGs translate to 40 bases that can be miscalled, which
occur at rates of approximately 0.04, or 4%, of aligned
reads. Comparing mean sample methylation between the
values reported by Bismark and those based only on the
reads we retained, the maximal absolute difference was
negligible, 0.6% or 0.006 (the median absolute difference
was only 0.13%).
Hierarchical Clustering of Samples Based on the Most
Abundant Patterns
The 1000 most frequent methylation patterns in each sample
were kept, with their union yielding 57,926 distinct patterns.
The union of the 30 most abundant patterns in normal and
30 most abundant patterns in tumor samples yielded 45
distinct patterns that were used in hierarchical clustering.
Selection of the most abundant patterns was based on
ranking the means of the pattern fractions across tumor and
normal tissue samples. On average, at least twice as many
single-C read patterns were observed in normal samples
than were expected from our estimates of inefﬁcient sodium
bisulﬁte conversion of fully unmethylated reads (P < 106,jmd.amjpathol.org - The Journal of Molecular Diagnostics
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terns are likely to be real events and not artifacts of
incomplete conversion.
The fractions of these 45 patterns across 218 samples
were log-transformed after replacing any fractions with a
value of zero with values represented by one-tenth the
minimal nonzero value for that pattern across all sam-
ples. To perform hierarchical clustering, we used the R
functions heatmap.2 (package gplots) and hclust (pack-
age stats) with the ward.D2 agglomerative clustering
method and Euclidean distance. Because the data were
log-transformed, distance was based on fold changes in
pattern fractions.
Calculation of Read Fractions with k Methylated CpGs
As stated previously, only sequence reads with 20 CpGs
(based on Bismark context calls) that aligned to the starting
coordinate chr19:58220404 were retained. In each sample,
sequence reads with equal numbers of methylated CpGs (0
to 20; ie, values of k), were counted together in the read
fractions (nk). The sum of all nk was normalized to 1. Using
the set of nk, we deﬁned the following ratios:
x Z n20/(n0 þ n20), (1)
yZn20=ðn20 þ
P5
kZ0nkÞ; (2)
and z Z (n19 þ n20)/(n0 þ n19 þ n20). (3)
Note that the mean mCpG fraction per sample can be
calculated as follows:
mZðP20kZ0knkÞ=ð20
P20
kZ0nkÞ. (4)
ROC Curve Classiﬁcation
We used the R package pROC to calculate area under the
receiver operating characteristic (ROC) curve (AUC) CIs
(using the default deLong method12). We used the R
package ROCR for convex hull calculation.13,14 The P
value for the AUC was obtained from a Wilcoxon rank
sum test evaluating the hypothesis that the distribution of
the ranks in the two groups (normal tissue and tumor
samples) is equal (if this hypothesis is correct, the AUC
should be 0.5).Dilution Simulations
We randomlymatched one of the 34 normal samples,Nj, to each
tumor, Ti, of the 184 tumor samples and mixed the two sample
signals together at a chosen fraction, f, yielding an in silico
diluted tumor value, Dij, where DijZ (1f )  Ti þ f  Nj.
Each Ti was randomly matched with one of the normal
tissue samples 100 times, resulting in a set of 18,400 in silico
tumor DNA dilutions. All Ti’s and Nj’s were represented as
vectors containing normalized frequencies nk of aligned reads
with given numbers of methylated CpGs (k between 0 and 20)The Journal of Molecular Diagnostics - jmd.amjpathol.organd methylation levels at each of the 20 CpGs. The fraction, f,
of normal signal in the mixture ranged from 0.1 to 0.99, with
intermediate values of 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9,
0.925, 0.95, and 0.975. In the ROC analysis, each dilution
level (or f ) was analyzed individually.
Machine Learning Classiﬁcation
We applied k-nearest neighbors (KNN) and support vector
machine (SVM) algorithms, using the three alternative
sample representations: i) methylation values at each of
the 20 individual CpGs, ii) the 45 most recurrent pattern
frequencies, and iii) frequencies of groups of patterns nk
with k methylated CpGs (0  k  20). For our compu-
tationally diluted data sets we used only the ﬁrst and third
representations.
Each representation was used as is or log-transformed.
To avoid inﬁnities due to log (0) in the latter case, we
tried three alternative thresholds, eZ {1e5, 1e3, 0.1},
and the data were transformed as log(data þ e). To
implement KNN algorithms, we used the knn.cv function
from the R package class, with 1, 3, 5, 7, or 9 nearest
neighbors; even numbers were omitted to avoid randomly
resolved draws. To implement SVM, we used the svm
function from R package e1071 and wrote a wrapper code
to perform the leave-one-out cross-validation. We set the
svm parameter class.weights as inversely proportional to
the class sizes used in training, with the mean set to 1, and
used ﬁve alternative cost values: 0.1, 1, 10, 100, or 1000.
Other parameters were assigned the default values; for
example, we used radial kernel.Results
Regional Assessment of ZNF154 DNA Methylation
Our previous analysis of DNA methylation data in TCGA
cohorts revealed that the ZNF154 transcription start site (TSS)
is hypermethylated in 15 different solid epithelial tumor types
compared with baseline methylation in normal tissue.8
Although all available probe sites from the Illumina 450 k
Inﬁnium methylation array were examined, the sparsity of
probes across the ZNF154 locus prohibited analysis of the
breadth of the hypermethylated region (HMR). We could only
estimate that the HMR was between approximately 750 and
11,700 bp long. However, whole genome bisulﬁte sequencing
data from matched tumor and normal colorectal tissue pub-
lished in the Gene Expression Omnibus (http://www.ncbi.nlm.
nih.gov/geo; accession number GSE46644) displayed a 1.5- to
2.0-kb region of tumor hypermethylation that centered around
the ZNF154 TSS (Figure 1A), and other samples showed a
similar HMR as well.15,16 On the basis of these data, we
designed a 302-bp PCR amplicon to cover a part of the
ZNF154 HMR we identiﬁed,8 including the TSS and part of
the associated CpG island (Figure 1, B and C). This 20-CpG
amplicon is positioned centrally in the tumor-speciﬁc HMR,287
Figure 1 DNA methylation proﬁle around the
transcription start site (TSS) of ZNF154. A and B: A
smoothed CpG methylation (mCpG) proﬁle in a
colon tumor sample (gray line) and adjacent
normal tissue (dashed black line), obtained from
whole-genome bisulﬁte sequencing data (A). The
rug plot illustrated along the bottom of the panel
marks all CpG positions (A). The TSS (vertical line,
A) and the amplicon interval (gray rectangle, A)
correspond to the region of the UCSC Human
Genome Browser (black rectangle, B). C: Genomic
positions of 20 CpGs in the 302-bp ZNF154
amplicon: enlarged view of the TSS region and
partial overlap with the annotated CpG island.
Margolin et alwhich should be optimal for distinguishing tumor from normal
samples.
Validation of Bisulﬁte Amplicon Sequencing
Reproducibility Using Cell Line DNA
The harsh conditions imposed by sodium bisulﬁte treatment
cause fragmentation and damage to DNA molecules, sug-
gesting that repeated sampling from very low quantities of
DNA could give variable results when drawn from the same
starting material. Therefore, we assessed the technical vari-
ability of our PCR ampliﬁcation method by sampling ampli-
ﬁable DNA molecules at very low amounts, simulating the
ampliﬁcation of low-copy-number tumor DNA fragments.17
For this purpose, we sampled genomic DNA at 20, 50, and
100 ng (in duplicate) from three replicate culture ﬂasks of the
tumor-derived cell line K562 and the non-tumor cell line
GM12878. We treated each sample with bisulﬁte, generated
PCR amplicons, added barcodes, and sequenced the products
on the Illumina MiSeq platform. Sequence reads were aligned
to a converted human genomic reference at the target locus
(hg19, chr19:58220404e58220705) using the tool Bismark.9
For GM12878, 16 samples yielded aligned reads totaling
1276 to 120,500 reads per sample at the amplicon locus with a
median of 23,460. For K562, 11 samples yielded aligned
reads, with 1796 to 237,900 reads per sample and a median
number of 26,480 (see Materials and Methods).
For both cell lines, MiSeq sequencing data across replicates
from different starting DNA concentrations revealed robust288methylation signals with minimal variation (Figure 2). The
consensus proﬁles of methylation at each CpG emerged from
overlap of 15 of the 16 GM12878 replicates and 10 of the 11
K562 replicates. Notably, for each cell line, one replicate fell
out of the consensus proﬁle. Excluding these outlier samples,
the mean percentage of mCpG for K562 cells was 40.7%
compared with 10.1% for GM12878. The SD of the per-
centage of mCpG at each of the 20 CpG dinucleotides was
small, ranging from 0.5% to 3.4% for GM12878 and 0.6% to
3.8% for K562. Moreover, the methylation trends were similar
to those observed in the Illumina array methylation data
generated by the ENCODE Consortium for K562 and
GM12878 at four probes in the same region (Figure 2).
Thus, methylation at ZNF154 discriminates a tumor-derived
cell line, K562, from a nontumor cell line, GM12878, derived
from the transformation of phenotypically normal human
lymphoblasts (P Z 2  105, Wilcoxon rank sum test,
including the outliers). Using as little as 20 ng of genomic
DNA, bisulﬁte amplicon sequencing produced reproducible
data with minimal deviation (approximately 2%) in methyl-
ation signal between technical replicates. Importantly, we
conclude that the use of technical replicates helps to ﬁlter
unreliable measurements.
Bisulﬁte Amplicon Sequencing in Solid Tumor
Gynecologic Samples
Next, we expanded our use of bisulﬁte amplicon
sequencing to investigate methylation levels at the ZNF154jmd.amjpathol.org - The Journal of Molecular Diagnostics
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Figure 2 Reproducibility data of amplicon
sequencing products from bisulﬁte-converted cell
line DNA. Results are shown for GM12878 (A) and
K562 (B) cell lines. Each line represents a different
replicate. Gray triangles represent the percentage
of CpG methylation (mCpG) at four CpG positions
present on the Illumina methylation array data,
generated from the same cell types by ENCODE.
ZNF154 Methylation Analysis and Modelinglocus in genomic DNA extracted from eight normal endo-
metrial samples and 42 endometrial tumors, comprising a
collection of 20 EEC, 11 serous tumors, and 11 clear cell
tumors.
A single technical replicate of each tumor sample was
assessed, and samples with at least 1000 aligned reads were
considered (excluding only one low-grade EEC sample with
402 aligned reads). By averaging the signal across the
amplicon, we found that tumors had a 66% increase in
median methylation levels relative to normal tissue
(P Z 2  105, Wilcoxon rank sum test) (Figure 3A). All
tumor stages were hypermethylated relative to normal tissue
(P  0.01, t-test). Stage IV tumors (one serous and one clear
cell sample) were hypermethylated relative to each of the
lower stages (P  0.05, t-test) (Supplemental Figure S1);
however, no signiﬁcant methylation differences were
observed among endometrioid, serous, and clear cell tumor
subtypes at this locus.
We compared Illumina methylation array data to bisulﬁte
sequencing data generated from these same samples and
found that the two array probes overlapping the amplicon
produced consistent results with the bisulﬁte sequence data
(Pearson correlation coefﬁcients of 0.96 and 0.97 and mean
differences of 5.7% and 3.9%) (Figure 3B and Supplemental
Figure S2). The agreement between the sequencing and0
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Figure 3 Comparison of CpG methylation (mCpG) levels in tumor and normal e
percentage of mCpG at each CpG position within the amplicon in normal (empty
1000 aligned reads. B: Scatterplot of tumor (T) methylation levels measured with
sequencing at the corresponding genomic position, chr19:58220494 (y axis), in th
all amplicon CpG positions for each normal (N) sample, plotted against duplicate
The Journal of Molecular Diagnostics - jmd.amjpathol.orgarray methylation values was strongest at very high
methylation levels (>80% mCpG) and more variable at
lower methylation levels (<40% mCpG). One advantage of
amplicon sequencing is the ability to assess bisulﬁte con-
version of unmethylated cytosines within the amplicon,
where incomplete conversion creates a false-positive signal
for methylation. We examined all Cs in non-CpG contexts
in our endometrial samples and found minimal non-
conversion (between 0.3% and 6.4% unconverted Cs at non-
CpG positions, with a median of 2.6%).
We observed several additional characteristics in the
sequencing data. For example, a slight decrease in median
methylation occurred in tumors across four CpGs that sur-
round the TSS (chr19:58220579) (Figure 3A), suggesting
that this area is more resistant to DNA methylation than
surrounding regions. In addition, the variability in percent-
age of methylation across samples was greater at each CpG
position in tumors than in normal tissue. The low variance
in normal samples was expected because of their lowered
heterogeneity compared with tumor samples. Finally, some
tumor samples had lower methylation levels than some
normal tissue samples (Figure 3A), with low percentage of
mCpG, which is consistent with reports from TCGA that
some tumors lack DNA hypermethylation proﬁles.18 How-
ever, all tumor samples had mean methylation levels higherT
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Figure 4 Distribution of individual CpG
methylation (mCpG) levels in lung, stomach, colon,
and breast tumor and normal tissue samples. A: Box
plots of the mean percentage of methylation,
determined from bisulﬁte sequencing, at each CpG
position within the amplicon in normal (empty
black) and tumor (shaded gray) samples. Samples
contained 1000 aligned reads. B: Scatterplots of
the mean percentage of methylation across all
amplicon CpG positions for tumor (T) and normal (N)
samples are plotted against duplicate values, when
both duplicates have at least 1000 aligned reads.
Margolin et althan the median level of the normal samples. Taken
together, these data conﬁrm that methylation levels at the
ZNF154 amplicon separate most uterine tumor samples
from normal samples.
Methylation Measurements in Lung, Stomach, Colon,
and Breast Tumors and Normal Tissues
Next, we assessed DNA methylation in lung, stomach, colon,
and breast tumor panels, each with 40 tumor and eight normal
tissue samples. All samples were examined in duplicate to
estimate measurement accuracy. As with our analysis of
endometrial cancer, we used samples that had >1000 aligned
sequenced reads, resulting in informative sample sizes of 46 for
lung cancer (40 tumor and six normal tissue samples), 40 for
stomach cancer (34 tumor and six normal tissue samples), 36
for colon cancer (30 tumor and six normal tissue samples), and
47 for breast cancer (39 tumor and eight normal tissue samples).290In each of these data sets, the mean methylation within the
amplicon region was greater in tumors than in normal tissue.
The median percentage of mCpG in normal samples was
20%, 8%, 19%, and 4% for lung, stomach, colon, and breast
tissue, respectively. In comparison, stomach and breast
tumors had 20% and 31% increases in median methylation
relative to corresponding normal tissue (P Z 3.0  104
and P Z 2.1  104, respectively; Wilcoxon rank sum test)
(Figure 4A). Colon and lung tissue had greater increases of
44% and 45%, respectively (P Z 3.9  104 and
P Z 4.1  106, respectively; Wilcoxon rank-sum test).
Thus, the four tumor types were consistently hyper-
methylated at this locus compared with normal samples. The
large magnitude of this hypermethylation bodes well for a
strong discriminant in each tissue type. Methylation mea-
surements between duplicates with >1000 aligned reads were
consistent (Figure 4B), and the replicate data strongly
correlated (Pearson correlation coefﬁcients, 0.966).jmd.amjpathol.org - The Journal of Molecular Diagnostics
Figure 5 Methylation patterns of aligned reads in tumor versus normal endometrial, colon, stomach, lung, and breast tissue samples. A: Frequency of the
45 most repeated patterns. Unmethylated cytosines converted to thymines appear as (.), whereas methylated cytosines that were protected from conversion
appear as (c). Each symbol represents the status of one of the 20 CpG cytosines in the amplicon. B: Hierarchical clustering of the samples based on these 45
patterns. Heat map coloring reﬂects the relative abundance of a given pattern across samplesdgoing from white to black in each row or pattern would
correspond to moving from the bottom upward in the merged tumor-and-normal box plot for that same pattern, similar to A.
ZNF154 Methylation Analysis and ModelingThe characteristics associated with these tumor data were
consistent with our previous ﬁndings. For example, the me-
dian methylation around the ZNF154 TSS (chr19:58220579)
revealed a decrease with higher methylation levels at the CpGThe Journal of Molecular Diagnostics - jmd.amjpathol.orgsites to the left and to the right. Variance was also greater in
tumor samples than normal tissue samples. Moreover, the
four tumor types included a subset of samples with methyl-
ation levels comparable to or below that observed for normal291
Margolin et altissue samples. One tumor sample in each of the lung,
stomach, and colon collections and three in the breast
collection had mean methylation levels below the median of
their respective normal tissues. This ﬁnding is consistent with
TCGA reports of tumor samples that do not reveal aberrant
DNA methylation.8,18 We also performed quality control
assessment of the samples and concluded that nonconversion
rates of cytosines to thymines in all non-CpG contexts were
extremely low, indicating that the false methylation rate was
low (between 0.2% and 1.2%, all medians 0.6%).
Each tumor panel in our analysis provided information on
tumor subtype and relative grade (differentiation level), as well
as patient age and sex. Using linear regression, we assessed
whether mean methylation was predicted by subtype (with or
without grade), age, or sex. All tumor types were hyper-
methylated compared with normal tissue samples (P < 0.05)
(Supplemental Figure S3). However, no statistically signiﬁcant
differences appeared between tumor subtypes, after correcting
for age and sex. Sex was associated with methylation levels in
stomach and colon tumors (where males tended to have
lower and higher methylation, respectively, than females)
(Supplemental Figure S4),withmarginally signiﬁcantP values
(0.055 for stomach and 0.051/0.016 for colon, using subtype
andgrade/subtype).Despite the small sample sizes for subtypes
and stages, we found some differences when comparing me-
dian methylation levels. For example, in lung, small cell car-
cinomas, and squamous cell carcinomas seemed to have 15%
greater median methylation than adenocarcinomas and bron-
chioalveolar carcinomas (although not reaching statistical
signiﬁcance at P Z 0.23, t-test). Moreover, we found 25%
greater median methylation in colon and lung adenocarci-
nomas relative to stomach adenocarcinomas (P< 0.02, t-test).
Adenocarcinomas represented a large proportion of the
subtypes in the endometrial (41/41), lung (11/40), stomach
(31/34), colon (30/30), and breast (39/39) tumors. This is not
surprising because adenocarcinoma is the most commonly
diagnosed tumor subtype for each of these tissues.19e22 When
analyzing only adenocarcinomas, tumors had a mean of 30%
hypermethylation in the lung and colon tumors relative to
normal tissue and>20% in breast and stomach tumors relative
to normal. In lung tissue, squamous cell and small cell0 2 4 6 8 11 14 17 20
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292carcinomas are associated with a history of tobacco use23 and
are considered aggressive tumors; they found even higher
median methylation levels in our data set. Breast tumors in our
study were predominantly represented by invasive ductal
carcinomas (33/39), which have a median methylation level of
34% compared with just 4% in normal breast tissue.Classiﬁcation of Tumor and Normal Samples Using
Methylation Patterns
To evaluate the ZNF154 CpG island (CGI) as a pan-cancer
marker for detecting tumors, we pooled the data from endo-
metrial, colon, stomach, lung, andbreast tissue samples, giving a
total of 34 normal and 184 tumor samples. We examined pat-
terns of methylation and compared their frequencies between
tumor and normal samples. Next, we assessed the performance
of various approaches for classifying samples as either tumor or
normal based on these pattern frequencies.
We began by recording the position of each methylated
CpG in each aligned read for every sample. The 20 CpG
positions in our amplicon provided 220 or >1,000,000
possible methylation patterns. Each pattern was represented
as a string of 20 characters encoding the methylation state of
each CpG in the amplicon as either methylated or unme-
thylated. We identiﬁed the 30 most frequent patterns across
normal samples and the 30 most frequent patterns across
tumors. Counting the 15 patterns common to both groups,
the union yielded 45 distinct patterns. These patterns fell
into two main categories: those with 0 or 1 methylated CpGs
and those with high numbers of methylated CpGs (18, 19, or
20). The low-methylation reads were frequent in both
normal and tumor samples, whereas the high-methylation
reads were primarily present in tumors (Figure 5A).
Initially, each sample was categorized as a tumor or
normal sample using this set of 45 patterns. In unsupervised
hierarchical clustering of samples (Figure 5B), we desig-
nated the left topmost branch as negative or normal sample
classiﬁcation and the right branch as positive or tumor
sample classiﬁcation. The true-positive rate of classiﬁcation
was 81%, with a false-positive rate of 6%.1 14 17 20
CpGs
Figure 6 Levels of CpG methylation (mCpG) of
aligned reads in tumor versus normal endometrial,
colon, stomach, lung, and breast tissue samples.
Frequency of aligned reads as a function of the
number of mCpGs, from 0 to 20, in normal (A) and
tumor (B) samples. Different patterns with iden-
tical numbers of mCpGs have been grouped
together.
jmd.amjpathol.org - The Journal of Molecular Diagnostics
AUC = 0.936 , P = 7.25x10-16
95% CI: 0.905 0.967 
Maximum(TPR FPR) cutoff = 
0.24 TPR = 0.83 , FPR = 0
AUC = 0.959 , P = 1.97x10-17
95% CI: 0.934 0.984 
Maximum(TPR FPR) cutoff = 0.059 
TPR = 0.81 , FPR = 0
AUC = 0.958 , P = 2.18x10-17
95% CI: 0.933 0.983 
Maximum(TPR FPR) cutoff = Maximum(TPR FPR) cutoff = 0.055 
0.04 TPR = 0.8 , FPR = 0
AUC = 0.946 , P = 1.55x10-16
95% CI: 0.917 0.974 
TPR = 0.88 , FPR = 0.059
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Figure 7 Distinguishing tumor samples from normal tissue based on DNA methylation in endometrial, colon, stomach, lung, and breast samples.
Cumulative distribution functions (CDFs) (top panel) and receiver operating characteristic (ROC) curves (bottom panel) are shown. CDFs of normal and tumor
samples are in black and gray, respectively, plotted against a logarithmic x axis. ROC curves reveal the point of the maximal sum of sensitivity and speciﬁcity
(gray dot). Each column contains CDFs and ROC curves corresponding to a different sample measurement, scaled to vary between 0 and 1. A: Mean fraction
(percentage per 100) of methylated CpGs per sample, m. BeD: The results for the x, y, and z ratios, respectively, deﬁned in the text. FPR, false-positive rate
(ie, 1  speciﬁcity); TPR, true-positive rate (ie, sensitivity).
ZNF154 Methylation Analysis and ModelingAlternatively, we binned all possible methylation
patterns by the total number of methylated CpGs per
read. With exactly 0 to 20 methylated CpGs, each
aligned read was placed into one of 21 possible groups.
We then used the normalized frequencies of aligned
reads in these groups to classify tumors. Their distri-
bution across normal and tumor samples is shown in
Figure 6. In normal samples, approximately half of
aligned reads were not methylated (Figure 6A), and
most of the remaining reads contained <10 methylated
CpGs. However, there was a tiny fraction of completely
methylated reads (median, 0.04% of reads). In tumors
(Figure 6B), completely unmethylated reads were less
common, at 19%, and completely methylated reads
were much more common than in normal samples, at
15%. All 184 tumors had completely methylated reads.
Unfortunately, the presence of completely methylated
reads in at least a subset of normal samples prevented
classifying tumors simply based on the presence of
these reads.
Finally, the frequency of all or a subset of these
methylation pattern groups was used to classify each
sample. We created ratios deﬁned by subsets of these
methylation pattern groups to assess the optimal classiﬁ-
cation approach (see Materials and Methods). WeThe Journal of Molecular Diagnostics - jmd.amjpathol.orgcompared the classiﬁcation performance of these ratios
with that of the mean methylation fraction per sample, m
(Figure 7A), using ROC curve analysis. This analysis
allows one to choose any desired speciﬁcity and sensi-
tivity represented along the curve. The two groups of
patterns that differed the most were fully unmethylated
and fully methylated reads. Focusing on just these two
groups, we deﬁned a ratio, x, to distinguish tumor from
normal tissue samples (Figure 7B). In the absence of
partially methylated reads, x would represent the mean
methylation fraction per sample, becoming identical to m.
We also combined fully unmethylated reads with reads
with low methylation (ﬁve or fewer mCpGs) to deﬁne the
ratio, y (Figure 7C). Similarly, we combined fully meth-
ylated reads with reads with near complete methylation (at
19 CpGs) to deﬁne the ratio, z (Figure 7D). The three
ratios, x, y, and z, performed similarly, with AUCs be-
tween 0.946 and 0.959. This represents marginal
improvement over the AUC value of 0.936 obtained using
m and indicates that the strongly discriminating signals
detected in tumor tissue can be classiﬁed using the mean
methylation level. Nevertheless, the same simplicity may
not apply to samples generated from circulating tumor
DNA where the tumor signal is likely to be diluted in a
background of nontumor signal.293
Figure 8 Performance of the four selected predictors (m, x, y, and z;
deﬁned in text) in distinguishing endometrial, colon, stomach, lung, and breast
tumors from normal samples at different simulated dilution levels. Area under
the receiver operating characteristic curve (AUC) is plotted as a function of
simulated tumor DNA dilution. The leftmost AUC values (when fraction of
normal DNA is 0) correspond to the data presented in Figure 7.
Margolin et alSimulation: Detection and Classiﬁcation of Dilute
Tumor DNA in Blood
Given our robust detection of hypermethylation in solid
tumor surgical resections from different cancer types, we
investigated the clinical relevance of the ZNF154 CGI locusFigure 9 Simulation: distinguishing endometrial, colon, stomach, lung, and b
are arranged as in Figure 7. Tumor signal characteristics (gray CDFs) were simula
Normal samples are the same as in Figure 7 (black CDFs). A: Diluted tumors were p
area under the receiver operating characteristic curve (AUC) of 0.54. BeD: By co
signal measures, x, y, and z (AUCs of 0.73, 0.75, and 0.63, from left to right). As
an increase in the AUC from 0.75 to 0.79. CDF, cumulative distribution functi
(ie, sensitivity).
294as a pan-cancer marker in a blood-based screening. We
constructed a collection of in silico data designed to simulate
dilution experiments using the data set generated from 34
normal tissue and 184 tumor tissue samples from panels
comprising ﬁve tumor types. Brieﬂy, each dilution sample
was generated by randomly and repeatedly matching each
tumor sample to a normal tissue sample, independent of
sample origins, and mixing their data together in a deﬁned
ratio. We varied the fraction of normal signal in the mixture
from 0.1 (10%) to 0.99 (99%), balancing the tumor contri-
bution from 90% to 1% of the input methylation signal. Each
dilution level gave rise to a separate data set. We assumed that
the low methylation signal observed in our 34 normal tissue
samples was a suitable approximation of methylation that we
may observe in normal blood, in agreement with data from
methylation array studies (eg, Gene Expression Omnibus;
http://www.ncbi.nlm.nih.gov/geo; data sets GSE64950 with
36 samples from six individuals and GSE55763 with 2711
samples from 2664 individuals).24 For example, the mean 
SD methylation of the four CpGs within the amplicon that are
also represented on the methylation arrays (Figure 2) was
12%  7% in our normal tissue samples, comparable to
the BMIQ-normalized25 measurements of 10%  5% and
6%  3% in the GSE55763 and GSE64950 data sets,
respectively.reast tumors from normal samples when tumor signal is diluted. The graphs
ted by mixing 1% tumor signal with 99% randomly picked normal signal.
ractically indistinguishable from normal samples when relying on m, with an
ntrast, the capacity for classiﬁcation persisted over dilutions for the other
an example of the use of the convex hull (gray off-diagonal line), C shows
on; FPR, false-positive rate (ie, 1  speciﬁcity); TPR, true-positive rate
jmd.amjpathol.org - The Journal of Molecular Diagnostics
ZNF154 Methylation Analysis and ModelingFor each set of tumor dilutions, we performed the same
classiﬁcation analysis as was performed for the original
tumor to normal comparison (Figure 7). The x and y ratios
yielded the highest AUC values for all dilution levels, from
0 (undiluted) to 99% (Figure 8). As shown in Figure 7, the
AUC for mean methylation, m, classiﬁcation was just
slightly below that for other predictors when considering
undiluted samples. However, it deteriorated much faster
than the others with higher dilution levels. The y ratio,
which incorporates aligned reads with one to ﬁve methyl-
ated CpGs, performed slightly but consistently better than x,
which is based solely on fully methylated and fully unme-
thylated reads. In addition to x, y, and z, we also considered
a classiﬁcation based on the fraction of fully methylated
read outs of all reads. This measure performed similar to z at
low dilutions, similar to x at intermediate dilutions, and
similar to y at higher dilutions (not shown).
At the dilution using 90% normal data, the ratios x and y
performed well, with AUCs of approximately 0.89, whereas
the AUC for the m-based ROC was much worse, at 0.68.
Even at the highest dilution considered, 99%, the x and y
ratios had substantial ability to discriminate between tumor
and normal samples, with AUCs of approximately 0.74
(P < 3  106, Wilcoxon rank sum test; 95% CI,
0.63e0.85) (Figure 9, B and C). At this dilution, the AUC
for the m-based ROC was only 0.54, near the value of
random guessing of 0.5 (P Z 0.42; 95% CI, 0.43e0.64)
(Figure 9A).
Finally, to estimate the classiﬁcation capacity of our
approach for individual tumor types, we performed dilution
simulations similar to those described above but with only
one tumor type present at a time. We used the same, pooled
set of normal tissue samples in each case, as an approxi-
mation of normal blood and to maximize the selection
(Supplemental Figure S5). Endometrial and colon tumors
were the easiest to classify, with the best AUCs, >0.95, up
to 90% dilution. Breast tumors were the hardest to classify,
with all AUCs at <0.90. In lung tumors, the AUC based on
m (mean methylation) performed better than the alternatives
(x, y, and z) at up to 70% dilution, but it quickly degraded at
higher dilutions. We note that the results of our analysis that
pooled tumors of all types together (Figure 8) reﬂected the
relative numbers of samples of each type.
By modeling the data anticipated from blood samples,
in which the ampliﬁcation of target ctDNA will be mixed
with target DNA from normal cells, we have explored
whether our methods have potential for clinical di-
agnostics. Even when tumors contributed just 1% to the
total methylation signal, we could discriminate tumors
from normal tissue samples using speciﬁc methylation
patterns at the ZNF154 CGI, with an AUC of 0.74
(Figure 9, B and C). A mathematical technique, con-
structing a convex hull, can improve the ROC curve and
increase the AUC13,14; this somewhat improved our
classiﬁcation performance to the AUC of 0.79 (Figure 9C
and Supplemental Figure S5).The Journal of Molecular Diagnostics - jmd.amjpathol.orgTumor Classiﬁcation Using Machine Learning
In addition to the straightforward classiﬁcation schemes
described above, we investigated how well we could distin-
guish tumors from normal tissue using KNN and SVM
algorithms. When we considered the solid tumor data
(Supplemental Figure S6), the performance of SVM using the
most abundant pattern frequencies was somewhat better than
hierarchical clustering performance (Figure 5B) using the
same data (ie, frequencies of the 45 most recurrent patterns).
Overall, however, KNN and SVM classiﬁcation performance
was similar across the three alternative representations
(Supplemental Figure S6) and, moreover, similar to the per-
formance based on scalar predictors m, x, y, and z deﬁned in
the main text (Figure 7). We also applied SVM and KNN
cross-validation to our computationally diluted data sets but
found no performance gain. For example, at 90% dilution,
SVM and KNN performance was at best comparable to that
of x- or y-based classiﬁcation, whereas at 99% dilution the
SVM and KNN predictions were often worse than a random
guess (true-positive rate less than false-positive rate) or had
severe underﬁtting26 (Supplemental Figure S7).
Thus, we conclude that machine learning classiﬁers pro-
vide no additional beneﬁt over approaches using simple
methylation ratios with respect to the classiﬁcation of tumor
versus normal tissue using methylation around the ZNF154
CGI. The advantage of the scalar predictors m, x, y, and z is
that they are easy to interpret and work with, which cannot
be said about the machine learning algorithms, which
require much more validation and parameter selection.Discussion
We used deep bisulﬁte sequencing to examine recurrent
hypermethylation around the ZNF154 TSS in ﬁve solid tumor
types: lung, stomach, colon, breast, and endometrium. We
conﬁrmed that the ZNF154 amplicon region was signiﬁcantly
hypermethylated in these tumor types relative to normal
samples. Furthermore, this hypermethylation occurred in most
tumors examined, regardless of subtype, stage of differentia-
tion, age, or sex. The discrimination between all tumor sub-
types and normal controls was most prominent in endometrial,
colon, and lung tissues (Supplemental Figures S1 and S3). We
did not have adequate sample sizes to thoroughly investigate
all subtype differences, except, perhaps, for endometrial tu-
mors, in which we have not observed differential methylation
among different subtypes. Therefore, further experimental
testingwith greater sample sizes and different tumor typesmay
reveal associations between ZNF154 methylation and tumor
subtypes, novel epitypes, disease pathology, or targeted
therapies.
Given the reproducibility of hypermethylation across a
breadth of solid tumor types and the sensitivity detected in
our simulated dilutions, we predict that the ZNF154 amplicon
can distinguish ctDNA in a blood-based test. Although295
Margolin et alpublished studies have detected and assessed the fraction of
ctDNA based on mutations,27e29 mutation detection requires
speciﬁc knowledge about the patient’s mutation, and at this
time it is not always clear what levels of ctDNA should be
considered abnormal or warrant intervention.3,30e32 Further-
more, it is difﬁcult to implement mutation testing in ctDNA
as a generalized diagnostic test for cancer because the mu-
tations are so varied. Presence of ctDNA has also been
detected and quantiﬁed using DNA hypermethylation.33
Consistent with this idea, we found that elevated methyl-
ation levels at ZNF154 appear to be prevalent across different
tumor types providing application as a generalized test while
potentially complementing ctDNA mutation testing applied
to speciﬁc cancer types.
Estimates of ctDNA amounts in blood vary widely, ranging
from fractions of a percent to most sample DNA.3,27e30,33 Our
computational simulation provides insight into how ZNF154
methylation analysis could be applied to blood samples. At a
simulated 90% dilution, in which the tumor contributes only
10% of DNA signal, classiﬁcation performance was good,
with AUCs of 0.89 (Figure 8) (x and y ratios). Even a simu-
lated 99% dilution yielded an AUC of 0.79. Because different
tumor types have different hypermethylation levels and pro-
ﬁles, both relative to their normal tissue controls (Figures 3
and 4) and to the pooled normal tissues, we observed the
best performance of the potential ZNF154 biomarker for the
endometrial and colon tumors (Supplemental Figure S5).
Overall, our in silico dilution estimates suggest that hyper-
methylation of the ZNF154 CGI region should be robustly
detected as long as the ctDNA fraction is at or above single-
digit percentage levels. Such sensitivity should be adequate
to detect advanced cancer and some intermediate and early
tumors, depending on the tumor type.30 We note that our solid
tumor DNA samples may themselves be a mixture of tumor
and normal cells, introducing an inherent dilution to the tumor
methylation signal and making our estimates overly
conservative.
We considered our methylation detection relative to other
detection techniques. Currently, the predominant method used
in DNA methylation-based cancer diagnostics is methylation-
speciﬁc PCR (MSP), including its quantitative variants
(qMSP).7,31,32,34e40 The qMSP approach assumes that all
CpGs in the targeted locus are either fully methylated or
unmethylated and aims to quantify these two patterns. By
comparison, our classiﬁcation approach based on the ratio x of
fully methylated reads to the sum of fully methylated and fully
unmethylated reads was among our best performers. When we
included partially methylated reads, only a modest improve-
ment occurred (Figure 8) (x is close to y), whereas including
near-completely methylated reads together with fully methyl-
ated reads led to decreased performance (Figure 8) (compare z
to x ratios). Of note, qMSP provides no way to avoid some
ampliﬁcation of incompletely methylated reads together with
fully methylated reads. Moreover, an amplicon of 300 bp is
atypically long for MSP. As a proxy, when we discarded the
ﬁve rightmost CpGs in the amplicon and reanalyzed our data,296the classiﬁcation performance decreased (Supplemental
Figure S8), indicating an advantage to using longer reads.
The largest decrease in classiﬁcation, compared with the
analysis using all 20 CpGs, was observed at the highest
dilution (99%), with a top AUC of just 0.64; however, the
classiﬁcation based on m (mean methylation) remained the
worst. Therefore, given all the considerations above, MSP
classiﬁcation performance is likely to be lower than the
method described here. Furthermore, recent work comparing
different methods of DNA methylation measurement has
found that sequencing reveals better precision than qMSP.41
In the case of actual (nondiluted) solid tumors, a simple
classiﬁcation based on mean mCpG (m) performed on par
with the ratio-based classiﬁers (x, y, and z), whereas for
diluted tumors the best classiﬁcation performance was
achieved using combinations of frequencies of methylation
patterns of individual DNA fragments (using x or y).
Classiﬁcation based on mean mCpG does not require such
detail, but it performs the worst (Figure 8). Because neither
arrays nor standard pyrosequencing (or Sanger sequencing)
generate the detailed data provided by bisulﬁte sequencing,
they will not provide optimal analyses. Likewise, other
groups using bisulﬁte amplicon sequencing did not quantify
methylation patterns of individual reads. This appears
problematic, given the random fragmentation of amplicons
generated there.10
Evaluation of ZNF154 methylation as a biomarker for
cancer will require direct measurement in body ﬂuids using
the method described here. Given that plasma cell-free DNA
fragments average <300 bp, our amplicon size might need
optimization.3 Another factor that may potentially improve
tumor detection is having internal DNA standards to quan-
tify the DNA concentration.40 This information could be
used to quantify the number of fully methylated reads per
unit volume of blood, which may serve as an additional
discriminative tumor signature. Ultimately, assessment of
early- versus late-stage samples will reveal the range of
diagnostic potential provided by this locus. We note that our
analyses use a comparison of tumor to unmatched normal
tissue samples, which precludes assessment of elevated
methylation levels in premalignant tissues. Detection of
premalignant tissue might in fact be beneﬁcial, although in
the context of a blood test we might see a hypermethylation
signal only if such DNA reaches the bloodstream. We also
note that we have not assessed tumor heterogeneity, which
could inﬂuence the median methylation levels we measure
in different tumor types.
In summary, bisulﬁte amplicon sequencing potentially
recovers all read patterns present in a sample, allowing a
more detailed analysis of methylation. With the use of this
approach, ZNF154 hypermethylation may represent a
pan-cancer biomarker for solid tumors and could poten-
tially be used to diagnose tumors through circulating
tumor DNA. A natural extension would then be tracking
the effectiveness of chemotherapy or tumor recurrence
using blood samples.jmd.amjpathol.org - The Journal of Molecular Diagnostics
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